INTELLIA THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
INTELLIA THERAPEUTICS, INC. (NTLA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $18.07 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- INTELLIA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $18.07M, a 17.98% decline year-over-year.
- INTELLIA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $13.48M, a 38.28% decline year-over-year.
- INTELLIA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $19.60M, a 50.52% decline year-over-year.
- INTELLIA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $22.04M, a 46.07% decline year-over-year.
- INTELLIA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $80.22M, a 48.00% decline from fiscal 2024.
- INTELLIA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $154.27M, a 15.09% increase from fiscal 2023.
- INTELLIA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $134.05M, a 46.66% increase from fiscal 2022.
- INTELLIA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $91.40M, a 94.43% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 8 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $18.07M 10-Q · filed 2026-08-06 | $31.55M derived: sum of 2 quarters · filed 2026-08-06 | |||
| 2026-03-31 | $13.48M 10-Q · filed 2026-08-06 | ||||
| 2025-12-31 | $80.22M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $19.60M 10-Q · filed 2025-11-06 | $41.64M derived: sum of 2 quarters · filed 2026-08-06 | $63.48M derived: sum of 3 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $22.04M 10-Q · filed 2026-08-06 | $43.88M derived: sum of 2 quarters · filed 2026-08-06 | |||
| 2025-03-31 | $21.84M 10-Q · filed 2026-08-06 | ||||
| 2024-12-31 | $154.27M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $39.62M 10-Q · filed 2025-11-06 | $80.48M derived: sum of 2 quarters · filed 2025-11-06 | $114.66M derived: sum of 3 quarters · filed 2025-11-06 | ||
| 2024-06-30 | $40.86M 10-Q · filed 2025-11-06 | $75.04M derived: sum of 2 quarters · filed 2025-11-06 | |||
| 2024-03-31 | $34.18M 10-Q · filed 2025-11-06 | ||||
| 2023-12-31 | $134.05M 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | $35.35M 10-Q · filed 2024-11-07 | $71.75M derived: sum of 2 quarters · filed 2024-11-07 | $99.01M derived: sum of 3 quarters · filed 2024-11-07 | ||
| 2023-06-30 | $36.40M 10-Q · filed 2024-11-07 | $63.66M derived: sum of 2 quarters · filed 2024-11-07 | |||
| 2023-03-31 | $27.25M 10-Q · filed 2024-11-07 | ||||
| 2022-12-31 | $91.40M 10-K · filed 2025-02-27 | ||||
| 2022-09-30 | $25.21M 10-Q · filed 2023-11-09 | $48.28M derived: sum of 2 quarters · filed 2023-11-09 | $66.77M derived: sum of 3 quarters · filed 2023-11-09 | ||
| 2022-06-30 | $23.07M 10-Q · filed 2023-11-09 | $41.56M derived: sum of 2 quarters · filed 2023-11-09 | |||
| 2022-03-31 | $18.49M 10-Q · filed 2023-11-09 | ||||
| 2021-12-31 | $47.01M 10-K · filed 2024-02-22 | ||||
| 2021-09-30 | $15.41M 10-Q · filed 2022-11-03 | $26.02M derived: sum of 2 quarters · filed 2022-11-03 | $32.45M derived: sum of 3 quarters · filed 2022-11-03 | ||
| 2021-06-30 | $10.61M 10-Q · filed 2022-11-03 | $17.04M derived: sum of 2 quarters · filed 2022-11-03 | |||
| 2021-03-31 | $6.42M 10-Q · filed 2022-11-03 | ||||
| 2020-12-31 | $19.90M 10-K · filed 2023-02-23 | ||||
| 2020-09-30 | $5.40M 10-Q · filed 2021-11-04 | $10.16M derived: sum of 2 quarters · filed 2021-11-04 | $14.32M derived: sum of 3 quarters · filed 2021-11-04 | ||
| 2020-06-30 | $4.76M 10-Q · filed 2021-11-04 | $8.92M derived: sum of 2 quarters · filed 2021-11-04 | |||
| 2020-03-31 | $4.16M 10-Q · filed 2021-11-04 | ||||
| 2019-12-31 | $15.09M 10-K · filed 2022-02-24 | ||||
| 2019-09-30 | $3.08M 10-Q · filed 2020-11-05 | $7.48M derived: sum of 2 quarters · filed 2020-11-05 | $12.07M derived: sum of 3 quarters · filed 2020-11-05 | ||
| 2019-06-30 | $4.40M 10-Q · filed 2020-11-05 | $9.00M derived: sum of 2 quarters · filed 2020-11-05 | |||
| 2019-03-31 | $4.59M 10-Q · filed 2020-11-05 | ||||
| 2018-12-31 | $17.05M 10-K · filed 2021-02-26 | ||||
| 2018-09-30 | $4.46M 10-Q · filed 2019-10-31 | $9.36M derived: sum of 2 quarters · filed 2019-10-31 | $13.46M derived: sum of 3 quarters · filed 2019-10-31 | ||
| 2018-06-30 | $4.90M 10-Q · filed 2019-10-31 | $9.01M derived: sum of 2 quarters · filed 2019-10-31 | |||
| 2018-03-31 | $4.11M 10-Q · filed 2019-10-31 | ||||
| 2017-12-31 | $15.32M 10-K · filed 2020-02-27 | ||||
| 2016-12-31 | $2.02M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $4.07M derived: sum of 2 quarters · filed 2019-02-27 | $6.71M 10-K · filed 2019-02-27 | ||
| 2016-09-30 | $2.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-01 | $4.70M 10-Q · filed 2016-11-01 | |||
| 2016-06-30 | $2.65M 10-Q · filed 2016-08-04 | ||||
| 2015-12-31 | $685.00K 10-K · filed 2018-03-14 | ||||
| 2014-12-31 | $308.00K 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |